(dutch w o r k in g g r o u p on g ro w th h o r m o n e ) 
The first GH dosage increase in groups B and C resulted in a significantly higher mean height velocity (HV) compared w ith con stant dose group A. During the third year, when the dose was raised again only in group C, mean HV was significantly higher in groups B and C than in group A, and in group C compared with group B. In year 4 only group C mean HV rem ained significantly higher th a n group A. The pattern of change in HSDSCA (Dutch-Swedish-Danish Turner references) was identical; however, in year 4 m ean AHSDSCa in group B also remained significantly higher th an group A. After 4 yr GH treatm ent, the following was determined. 1) The m ean AHSD3ca was significantly higher for groups B and C compared with group A, but not significantly different between groups B and C. 2) Although significantly higher compared with estim ated values for u n treated Dutch girls w ith TS, bone m aturation of the GH treated girls was not significantly different between groups. 3) It was positively related with the degree of bone age (BA) retardation a t sta rt of study and negatively with baseline CA. 4) Both the modified Index of Potential H eight (m IPH RUS) and a recently developed Turner-specific final height (FH) prediction method (PTSRUs)* based on regression coeffi cients for H, CA, an d bone age, showed significant increases in mean F H prediction, w ithout significant differences betw een groups. PTSrus values w ere m arkedly higher th a n the m IPH RUS values.
Dose dependency could be shown for the area under th e curve (AUC) for GH, b u t AHSDSCa was n°t linearly related w ith AUC. Baseline G H binding protein (BP) levels w ere in 84% of the cases w ithin th e norm al age range; th e decrease in m ean levels after 6 m onths GH was n o t significant. M ean insulin-like growth factor I (IGF-I) an d IGFBP-3 plasm a levels increased significantly, w ithout significant differences betw een groups. AHSDSca during GH was dependent on IGF-I plasm a levels a t baseline and during the study period, |3-0.002 and /3-0.0004. Thus, a stepwise GPI-dosing approach reduced th e "w aning" effect of the grow th response after 4 yr tre a t m ent w ithout undue bone m aturation. F H prediction was not signif icantly different betw een tre atm e n t groups. Irrespective of the GH dose used, initiation of GH tre a tm e n t a t a younger age was beneficial after 4 y r GH w hen expressed as actual cm gained or as gain in FH prediction, b u t was not statistically significant w hen expressed as AHSDSpA over th e study period. S TUNTED growth is an almost invariable hallmark of girls with Turner syndrome (TS). Although these girls are not clearly GH-deficient (GHD) (1) (2) (3) (4) , GH therapy results in a marked increase of height velocity (HV) (5) (6) (7) . Studies in GHD patients (8) (9) (10) and in TS (5) (6) (7) (11) (12) (13) have shown that the growth response to GH treatment is dependent on the dose and frequency of administration. Frasier et al. (14) re ported in a 1 yr, parallel study in prepubertal GHD children that doubling the GH dose of 30 mU / kg thrice weekly im resulted only in a 1.3-fold increase of the first year HV. Also in TS, daily GH injections were more effective than the same weekly dosage in two or three weekly injections (12) . In the past years, the most commonly used GH dosages in TS varied from 2-4 IU /m 2 body surface/day sc (5-7, 12, 15) , where 4 IU /m 2 is equivalent to 0.045 mg /kg. In studies using GH dosages only, up to 4 IU /m 2/day, the growth rate outweighed the accelerated bone maturation (13, 16) , and thus,
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final height (FH) prediction improved more than with lower GH doses (5, 7, 12, 15) . An earlier GH treatment study of girls with TS in the Netherlands (16) showed a doubling of the HV in the first year of treatment with 4 IU G H /m 2/day com pared with pretreatment values. However, this increase could not be maintained during the subsequent years of treatment. This so-called "waning" effect has also been re ported by others (10, 17) . In GHD patients, a similar effect is observed, which can be overcome by a 2-to 3-fold increase of the GH dose (10, 18) . Furthermore, studies in GHD patients have demonstrated the importance of early diagnosis and therapy. GH treatment prevented further loss of stature but could not make up the deficit at diagnosis (19) . The previous Dutch studies of Turner syndrome confirmed that the growth response in younger girls was better than in older girls (12, 13, 16) . In contrast to the logarithmic relationship between GH dose, given thrice weekly im, and HV in GHD children, the effect of GH on insulin-like growth factor (IGF)-I plasma levels has been shown on a linear scale between 0 and 3 IU GH / m2 / day in GHD adults (20) . In the present study of TS, this concept is extended to the 4 -8 IU /m 2/day GH range.
To optimize GH treatment in TS, we investigated whether 1) a yearly stepwise increment of the GH dose could maintain or augment the initial increase in HV and thereby improve FH prediction. In addition, we investigated whether 2) treat ment from a young age onwards could improve FH predic tion. Moreover, in a subgroup of 12 girls the GH-IGF-T axis was studied in detail under GH treatment.
Subjects and M ethods

Study group
Sixty-eight previously untreated girls with TS were enrolled in a 4-yr, multicenter GH dose-response study. The diagnosis was confirmed by lymphocyte chromosomal analysis. Clinical data and karyotype of the girls are listed in Table 1 . Inclusion criteria were: a chronological age (CA) between 2 and 11 yr, height below the 50th percentile for Dutch children (21) , and a normal thyroid function. Exclusion criteria were: associated endocrine and / or metabolic disorders, growth failure caused by other disorders or emotional deprivation, hydrocephalus, previous use of drugs that could interfere with GH therapy, and Tanner puberty stage of at least B2 (22) . No provision was made with regard to the baseline GH stimulation tests.
Study design
The girls were randomized into three GH dosing groups with strat ification according to CA and height standard deviation score (HSDSCA):
A. (n = 23) 4 IU /m 2 body surface (equivalent to 0.045 m g/kg)/day for 4 yr, B. (n = 23 ) 4 IU/m2 in the first year, followed by 6 IU/m2/day during the second through fourth yr, C. (n = 22) 4 IU/m2 in the first year, 6 IU/m2 in the second year, and 8 IU/m2/day during the third and fourth yr.
Biosynthetic (B)-hGH (Norditropin, Novo Nordisk A/S, Denmark) was given sc at bedtime by means of a pen injection system (Nordiject 24). None of the girls received estrogens during the 4-yr study period. Written, informed consent was obtained from the parents or custodians of each child. The study protocol was approved by the Ethics Committee of each participating center.
Growth evaluation
Height measurements were determined at baseline and three times per. month by one investigator (A,T.) according to the methods of Cam eron (23), using a Harpenden stadiometer. Height was expressed as SD-Score for CA (HSDSCA/ HVSDSCA) using the Dutch-Swedish-Danish (DSD) Turner data (24) or reference data of normal Dutch (21) girls. The gain in height for untreated girls with TS was estimated from the equa tions of the DSD Turner data (24) , in which the height of an average girl with TS is indicated by her CA. Midparental height (MPH) was adapted for Dutch reference data (21) with the addition of 3 cm for secular trend: MPH = 1 j 2 X (Hmother + H falher -12) + 3 cm. The degree of obesity was expressed as body mass index (BMI) s d score (25) . Bone age (BA) was determined by one investigator (A.T.) according to Tanner & Whitehouse radius, ulna, short-bones (RUS) score (26) . Bone maturation (ABA/ ACA) was compared w ith estimated values from the equations of untreated Dutch Turner girls (27) ; in these equations the BA of an average girl with TS is indicated by her CA. FH prediction was estimated using the modified Index of Potential Height (mIPHRUS) method (28, 29) and a recently developed Turner-specific method (PTSRUS) (29) . Both methods comprise Dutch Turner references. Analoguous to the Tanner and Whitehouse mark 2 FH prediction method for normal children, the PTS method gives smoothed regression coefficients for H, CA, and BA.
Biochemical parameters
At baseline all girls underwent a GH provocation test. Arginine 0.5 g/kg body weight was infused in 30 min. Blood samples were drawn at 15-min intervals from -15 to +60 min and every 30 min during the second hour.
At baseline, 6 months after initiation of GH, and 6 months after each GH dosage increase, a 24-h GH profile was performed in a subgroup of 12 girls of group C. Starting at 0830 in the morning, blood was with drawn from an indwelling venous catheter with a heparin lock. Blood was collected every 20 min for GH measurement, and at the start a single additional sample was obtained for measurement of IGF-I and IGFBP-3, The girls kept normal diets served at hospital mealtimes and kept normal activity and sleeping habits. GH was injected before going to bed. At the above study time points blood was collected from all girls for the de termination of IGF-I and IGFBP-3, and at 42 and 48 months only for IGF-I. GH binding protein (GHBP) was determined at baseline and 6 months after initiation of GH therapy. All blood samples were stored on ice for no more than 3 h until centrifugation. The plasma samples were frozen (-2 0 C) until assayed.
Hormone assays
The RIA measurements of plasma GH, IGF-I, and IGFBP-3 were performed as described previously (30-32). The 95th percentile for peak pubertal levels in a normal female population for IGF-I and IGFBP-3 are ■ VAN TEUNENBROEK ET AL.
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700 ju,g/L and 5 m g/L, respectively. Plasma GH binding protein (GHBP) was determined by ligand-mediated immu nofunctional assay (LIFA) (33, 34) . All measurements were performed in the same laboratories.
Statistical analyses
Results are expressed as mean ( s d ), unless indicated otherwise. Dif ferences between groups were tested by Student's t-tests or by a oneway ANOVA (followed by the Student-Newman-Keuls test for multiple comparisons between groups at the P = 0.05 level). Differences between points in time were tested by paired Student's Ntests. The Kruskal-Wallis test was used to test for differences between stimulated maximum GH levels and Tanner breast-stage groups, the Chi-square test for differences between karyotype groups (45, X, and others). Correlations were tested with Pearson's linear correlation coefficient. For this purpose, IGF-I and IGFBP-3 plasma levels were transformed into log-values. To study the relation between growth response variables (the change in HSDSCA, HVSDS, bone maturation, or PTSRU5) and growth parameters measured at baseline [CA, BA, BA retardation (= CA-BA), HV, maximal GH peak after stimulation, s d scores for BMI, H, and HV], adjusted for the dose regimen (i.e. group), multiple linear regression (MLR) analyses were used. Statistical procedures were performed using the SPSS/PC + pro gram version 4.0 (SPSS Inc, Chicago, IL). A repeated measures ANOVA model (adjusted for dose-increment steps and duration of treatment) was used to determine the influence of baseline IGF-I levels on those during GH therapy and of IGF-I levels (at baseline and during GH therapy) on HSDSCA during GH therapy, using BMPD module 5V. A P value of less than 0.05 was considered significant.
The spontaneous 244i GH profiles at baseline were analyzed with the Pulsar program developed by Merriam and Wachter and described previously (30) . The area under the curve (AUC) was determined after the GH injection at 1600 h using the trapezoideal rule. The total body clearance was calculated from the injected dose divided by the AUC. The time interval from GH injection to maximum GH levels was recorded as Tmax. To determine the elimination half-time (t1/2) a linear regression analysis was performed on the GH levels starting from 1 h after T, max'
Results
Clinical data
In each group only one girl dropped out of the study for the following reasons: noncompliance, alleged increase of muscle mass and decline in school performance, and desire to initiate estrogen therapy before the end of the study pe riod. Eight girls changed during the course of the study from Tanner puberty stage B1 to B2, at a median age of 13.2 (range 10.9-15.0) yi\ Their distribution among the treatment groups A, B, and C was 2, 4, and 2 girls, and among karyotypes (45, X and others) 4 and 4 girls, respectively. There were no significant differences between these girls and the girls with out signs of endogenous estrogen production with respect to growth response and bone maturation after 4 yr GH therapy within each dose group, The number of adverse events was small, all were mild and transient.
Growth response
Compared with pretreatment, mean HV increased signif icantly for all three groups from about 6 cm /yr to 10 cm /yr in die first year of GH therapy. Thereafter, a waning of the growth response was observed (Fig. 1) . In the second year mean HV in groups B and C on a 50% higher GH dose were significantly higher compared with group A. When subse quently, in group C only, the dose was increased once again, mean HV in groups B and C were both significantly higher than in group A, but in group C also significantly higher compared with group B. In the fourth year of GH treatment pfil Èmm only in group C the mean HV remained significantly higher than group A. During the first year of treatment 29% of all girls managed to double their HV. If the growth response is represented as change in HVSDSca relative to prestudy values (see Table 1 ), AHVSDSca in groups B and C was significantly higher than in group A in the second through fourth year of GH therapy. However, in the third and fourth year AHVSDS in group C was not significantly different from group B.
After the first dose-increment for both groups B and C, the change in HSDSCA from the first year was significantly higher for the combined groups B and C compared with group A (P < 0.0001). The second dose-increment in the third year of treatment, as well as in the combined third and fourth year, resulted in a significantly higher change from year 2 in HSDSca for group C compared with group B, P values 0.04 and 0.02. The increase in mean HSDSCA was highest in the first year of GH (>1 s d s ), without a difference between groups (Fig. 2) . In the subsequent years of treatment, the change in mean HSDSCA showed the same pattern as that of HV. The mean increment in HSDSCA over 4 yr was signifi cantly higher for groups B and C compared with group A. However, the gain was not significantly different between groups B and C ( Table 2 ). The change in HSDSCA after 4 yr was unrelated to karyotype. When the gain in height was corrected for the estimated gain for untreated girls, the re- suits were similar (Table 2 and Pig. 3). The range of the gain in height over estimated untreated values for all girls was 5.5-21.9 cm; for four girls (all Group A), it was below 10 cm.
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Bone maturation
The change in RUS BA over the change in CA was not significantly different between groups over 4 yr (Table 2) , nor during any individual year of treatment. The mean values differed somewhat between the years: for all groups the highest advance was found during the third year and the lowest during the fourth year of GH (data not shown). Com pared with estimated values for untreated TS girls, bone maturation of the GH treated girls was significantly higher in every year, except for group A in the second and fourth year; for 4-yr results see Fig. 3 . There was no significant difference in the change in bone maturation over 4 yr be tween the girls with breast-stage B1 and B2 within groups. Bone maturation after 4 yr of treatment was positively related with the degree of BA 1'etardation at start of study (/3: 0.12) and negatively with baseline CA (0: -0.04).
Final height (FH) prediction
Mean FH prediction increased significantly for all groups after 4 yr GH treatment (Table 2) ; values with the FTSrus method were markedly higher compared with the mIPHRUS method. Significant differences between groups for the 4 yr change in either FH prediction method were not found, though mean values with both methods in groups B and C were higher than those in group A.
GH measurements
Baseline Arginine-stimulated GH plasma levels ranged from 3-74 mU/L ( Table 1 ). The stimulated GH levels (mU/L) were subdivided in the following level-ranges: less than 10, at least 10 and less than 20, and at least 20, with 9,28,31 girls, respectively. These numbers were similarly distributed among the 3 treatment groups. The girls with maximum stimulated GH levels below 20 mU / L did not differ signif icantly from those with normal stimulated levels (>20 mU/L) in their growth response expressed as the change in HSDSCA after 4 yr of GH treatment. Maximum stimulated GH levels were significantly negatively correlated with BMI-sd score at baseline (r = -0.31, P = 0.01). At baseline, the spontaneous and stimulated maximum GH levels in group C were not significantly different and were positively correlated (r = 0.5, P = 0.05). Table 3 includes some of the calculated variables of the spontaneous 24-h GIT profiles of 12 girls of Group C (at baseline). There was no correlation between any of these characteristics and prestudy HSDSCa* Furthermore, the characteristics of the 24-h GH profile tests 6 months after each dose-increment are shown. There was a significant, dose-dependent increase of the maximum GH level and the AUC. In contrast, the Tmax, the clearance, and the elimination half-life were not significantly different be tween the 3 GH doses. The latter is indicated by the par allelism between the curves after the maximum has been reached (Fig. 4) .
GH binding protein (GHBP)
Baseline measurements showed no differences between groups (Table 4) , the mean (s d ) for all girls being 229.4 (127.1) pmol/L. Compared with girls in a normal population (34) , 85% of the study group had GHBP levels within the normal age range, 9 girls (14%) had levels that were above normal, and only 1 girl (l%)had levels below normal. Baseline GHBP levels as well as the change from baseline after 6 months were not significantly different between the girls with stimulated GH levels above or below 20 mU/L. GHBP levels after 6 months treatment did not differ significantly from baseline. No of peaks, num ber of peaks; m ean GH, overall m ean GH plasm a concentration; m ax GH, m axim um GH plasm a concentration; AUC, area under the time-concentration curve; clearance, total body clearance; t 1/2, elim ination half-time; T nmx, tim e to peak value. Values in parentheses are high and low.
a Significantly greater compared with 4 IU/m2/day at P < 0.05 level. b Significantly greater compared with 6 IU/m2/day at P < 0.05 leveL
The ratio of IGF-I and IGFBP-3 levels showed an increase over time, but there were no significant differences between groups. Log-values of IGF-I and IGFBP-3 levels both at base line and their change after 30 months revealed a significant correlation (r = 0.76, P < 0.0001 and r = 0.25, P = 0.04, respectively).
Time' (hrs) Fig. 4 . Mean 24-h GH plasm a curves (logarithmic scale) vs, tim e for each of the three GH dosages ( 4 IU -E3-, 6 IU --f--*, and 8 I U -< $■ -) employed in a subgroup of 12 girls of Group C, 6 m onths after initiation and following each GH dose-increment.
IGF-I and IGF binding protein-3 (IGFBP-3)
At each time-point large interindividual differences ex isted within groups (Table 4) . Mean baseline IGF-I level of group B was higher compared with the other groups. Within groups, each point in time was significantly higher than the previous, except for 30 months (all groups) and 42 months (group B). Not until 30 months after the start of therapy did IGF-I levels (adjusted for baseline levels) for groups B and C become significantly higher compared with group A (P < 0.004), but at 48 months only group C was still significantly higher than group A (P = 0.008). The repeated measures model showed that the change in IGF-I levels during GH therapy was dependent on the dose, the duration of treat ment, and baseline IGF-I level.
At baseline, mean IGFBP-3 levels for group B were higher compared with the other two groups. After adjustment for baseline, IGFBP-3 levels were not significantly different be tween groups (Table 4) . Mean IGFBP-3 levels only increased significantly after 6 months of treatment (P < 0.0001). At the end of study 31% of the girls had plasma IGF-I levels and 35% had IGFBP-3 levels higher than the 95th percentile for normal girls at the pubertal peak. There were no differences between treatment groups.
Determinants of growth response
Multiple Linear Regression analyses showed that there were no significant relationships between 1) HVSDSCA in the fourth year GH (dependent variable) and pretreatment HVSDS; 2) the change in HSDSCA after 4 yr GH (dependentvariable) and baseline: CA, BA RUS, BA retardation, HSD-SCA, or Arginine-stimulated maximum GH levels (/3 = -0.008; P = 0.07); and 3) prestudy HV or HVSDS and base line IGF-I, or IGFBP-3 levels, or between the IGF-I to IGFBP-3 ratio. However, the 4-year change in HSDSCA was signifi cant, negatively related to baseline IGF-I and IGFBP-3 levels and their ratio (/3-values -0.006, -0.32, and -0.015, respec tively); even when the baseline IGF-I and IGFBP-3 concen trations were expressed as s d score relative to CA only for the girls with a baseline CA below 10 yr (n = 64). The change in HSDSca after 30 or 48 months GH treatment was also sig nificant, positively related to the change in IGF-I, and IG FBP-3 levels after 30 months of GH treatment, but not to their ratio. The repeated measures model with dose-increment steps and duration of treatment as covariates also showed that the change in HSDSCA during GH therapy was depen dent on IGF-I plasma levels at baseline and during the study period (/3 -0.002 and /3 0.0004). The gain in height over estimated untreated values at the end of the study (depen dent variable) was significantly negatively correlated (P < 0.0001) w ith age at start of treatm ent The change in PTSrus after 4 yr GH (dependent variable) was significantly nega tively related with CA or BA retardation at the start of the study, as well as with bone maturation during the study period. Finally, there was no linear relationship between 1) the change in HSDSCA and in the plasma GH AUC at each corresponding point in time; 2) the change in IGF-I or IG-FBP-3 plasma levels, or in the IGF-I to IGFBP-3 ratio and the change in AUC at each corresponding point in time; and 3) baseline GHBP levels and baseline CA, HSDSCA, HV, stim ulated GH levels. Only GHBP levels and BM1-SDS at the start of treatment were related (r = 0.45, P = 0.003). 
D iscu ssio n
Growth response
The present study shows that raising the GH dose in sub sequent years results in a significant, dose-dependent in crease of linear growth expressed as HV or HSDSCA. After 4 yr of GH treatment only the higher dose groups B and C differed significantly from the constant-dose group A, in terras of gain in cm, and expressed as the change in HVSDSCA (relative to baseline) and in HSDSCA; however, after 4 yr, group C was no longer different from group B. Although during the course of the study bone maturation proceeded significantly faster than that estimated in untreated girls, there was no significant difference between the treatment groups. Bone maturation was negatively related with base line CA and positively with the degree of BA retardation. The gain in height outweighed the increase in bone maturation, therefore FH prediction improved markedly, the magnitude being dependent on the method used, but not significantly different between groups. Age, BA RUS, BA retardation, or HSDSCA at start of therapy was not related to the change in HSDSCA over 4 yr in this study group aged 2-11 yr. On the other hand, the gain in height over estimated untreated val ues as well as the change in PTSrus after 4 yr of GH treatment were negatively related to prestudy CA, BA RUS, or to the change in bone maturation. A repeated measures model showed that each yearly change in HSDSca significantly correlated with IGF-I plasma levels.
Dose-response studies
Dose-response relationships in GH-deficient patients have been described earlier (20) . De Muinck Keizer-Schrama et at (10) reported in GHD children a significantly higher HVSDS and HSDSCA in 17 transfer patients (previously treated with 12 IU G H /m 2/ week) on 4 vs. 2 IU G H /m 2/ day. Preliminary reports in TS indicated that the increase in HV outweighed the increase in bone maturation and therefore FH prediction was more marked and sustained with higher GH dosages (5, 7, 15) . However, a comparison with other studies is difficult because of the differences in design and GH dose, entry criteria (e.g. a lower limit for GH provocative testing), age at start of treatment, variables and duration of study reported, and reference populations used. Takano et at (15) investi gated two constant GH dosage regimens in prepubertal gixls with TS, 0.5 and 1.0 lU /kg/w eek (comparable with 2 and 4 IU /m 2/day). Dose-dependency was shown by the signifi cantly higher mean change in HVSDS (Japanese references) during the first 4 yr in the highest dose group, in which the dose was similar to group A in the present study, compared with the lower dose group. In the fourth year of treatment HV in the highest dose-group was no longer significantly higher compared with the lower dose-group. The same phe nomenon might also develop in our study, since after a prolonged period on fixed doses, only the HV in group C remained significantly higher compared with group A in year 4. Nonetheless, this may already have resulted in a substantial difference in height gain. Since the mean change in HVSDS during the fourth year (see Table 2 ) was well above zero, the girls still exerted catch-up growth. Only 8 girls showed signs of pubertal development at a median age of 13.2 (range 10.9-15.0) yr. There were no significant differ ences between this group and the prepubertal girls with respect to growth response and bone maturation after 4 yr GH therapy.
Although FH prediction methods all have their inadequa cies, it has been shown in a previous report (29) that the mIPHRUS and PTSRUS methods have the lowest mean error compared with the FH actually reached by girls with TS, Furthermore, FH prediction methods should not be used during growth promoting therapy, since they are based on spontaneous growth. However, since mIPHRUS and PTSrus both include CA, BA (RUS), and height for the estimation of FH, they reflect the influence of GH on growth as well as bone maturation. In the present study both methods showed significant increases in mean FH prediction after 4 yr of GH therapy, without significant group differences. Only a trend towards higher values could be observed in the higher dosegroup s (B and C) for both the actual and estimated (FH prediction) cm gained.
Chaussain et at (6) performed a study in TS (CA ranged from 5-15 yr) with a GH dose of 0.7 IU /kg/w eek (about 3 IU / m2/ day). If HV after 6,12, or 24 months had not doubled, this dose was increased by the same amount (to a maximum of 2.1 IU/ kg/week). Fourteen of those 24 girls (58%) and 49% of all girls in the present study were unable to double their HV on 4 IU G H /m 2/day after 6 months, and 71% not after 1 yr (data not shown). After 3 yr, 12 out of the 22 girls (55%) were on the maximum GH dose. In agreement with the present study, increasing the GH dose did not lead to an acceleration of bone maturation, and FH prediction was therefore improved. ► 
GH, IGF-I, and their main binding proteins
In general, spontaneous as well as stimulated (3/ 35,36) GH levels in prepubertal girls with TS have been reported as being near normal (2, 4, 35, (37) (38) (39) . Despite differences in the assays used, both spontaneous and stimulated GH plasma levels were comparable with, those in prepubertal Dutch TS girls in another study (4) . In the present study the maximum GH levels after arginine stimulation were similar between groups, but the range was very wide (3-74 mU/L). Fifty-four percent of the girls had a maximum level below 20 mU/L, the cut-off point generally accepted to define GH deficiency. Although the mean BMI-sd score was close to zero in these girls (Table l)y obesity could explain the rather low maximal GIT levels in these girls (3, 40, 41) , since a negative correlation between stimulated GH levels and baseline BMI-SDS was found. Although representing only a single test, stimulated GH levels were related to the change in HSDSCA after 4 yr GH treatment at the 0.07 level of significance. This is in agreement with a report in normal children (42) and in disagreement with a Japanese report in TS (3) .
At baseline, a good correlation between spontaneous and stimulated maximum GH levels was observed in a subgroup of 12 girls of group C, in accordance with a previous report (41) . Compared with prepubertal Dutch TS girls in an earlier study (4) , and assuming a conversion factor from jwg/L to m U /L of 2, maximum GH levels were comparable (25.6 vs. 27.6 mU/L), mean 24-h GH levels were rather low (4.3 vs. ± 6.0 m U/L), and the mean num ber of peaks was high (10.2 vs. 4.5) in the present study. It has been suggested (4) that an elevated spontaneous pulse frequency pattern might be associated with rela tively low IGF-I levels and slow baseline growth and that these girls might benefit most from GH treatment. This seems in line with the present study. Furthermore, the change in HSDSCA after 4 yr GH treatment was negatively related to baseline IGF-I and IGFBP-3 levels (or their s dscores for CA) or their ratio.
In agreement with earlier short-term findings in GHD patients (20) , a clear-cut increase in maximum GH plasma levels and AUC values was observed during GH treatment with increasing dosages. The elimination half-time, however, was similar between the three GH dosage regimens, sug gesting that increasing the GH dose results in a higher bio availability of GH without accumulation. In addition, injec tion of higher dosages (and volume) did not result in a delayed time to maximum plasma GH levels. Nevertheless, in this small subgroup of girls the change over time of the plasma GH AUC was not significantly related to the corre sponding growth response expressed as change in HSDSCA nor to the corresponding change in IGF-I or IGFBP-3 levels or their ratio.
Except for the 30 months tim e-point in group B, IGF-I levels showed a progressive significant increase during the 4 treatment years, which in part can be explained by the age-dependency of this measurement. At 48 months only group C still had significantly higher IGF-I levels (adjusted for baseline) than group A (P = 0.008). In a report after 3 yr in Japanese girls with TS (43), mean IGF-I levels were sta tistically higher with 1 IU GH / kg / wk than with 0.5 IU /k g / wk. In the present study the change in IGF-I levels after 4 yr GH therapy was dependent on the dose, the duration of treatment, and the baseline IGF-I level. Thirty-one percent of the girls had plasma IGF-I levels after 4 yr GH of more than P95 for norm al girls at the pubertal peak, w ithout signif icant differences betw een groups. Only two of these girls were younger than 10 yr. At a lower GH dose than used in group A in the present study (0.68 IU /k g /w k ) Ranke et al (44) reported 15% of the TS girls to have IGF-I plasma levels above the pubertal peak after 1 yr. Moreover, base line IGFBP-3 plasm a levels in that study hardly deviated from the normal range, bu t after 1 yr of GH therapy more than 20% of the girls had IGFBP-3 levels above the pubertal peak. In the present study, determ ined in the same labo ratory, at baseline only 3, and after 30 m onths 23, girls (35%) had IGFBP-3 levels greater than 5 m g /L (P95 at peak pubertal level), w ith a similar distribution between the groups. IGFBP-3 w as not determ ined at 42 and 48 months, but a plateau seemed to have been reached after 6 months of therapy, despite age-dependency of this binding protein and a further increase of the GH dose. Baseline log-values of IGF-I vs. IGFBP-3 levels show ed a significant positive correlation (r = 0.75; P < 0.0001), but also the change of these values after 30 m onths from baseline was signifi cantly positively correlated (r = 0.25; P = 0.01). This is in line w ith earlier findings in TS (44, 45) , and not unex pected, since both proteins are GI~I dependent. A progres sive rise of the IGF-I to IGFBP-3 ratio could be an indicator of the grow th response (44) . However, after 30 or 48 m onths of treatm ent neither was a significant relationship observed betw een the change in IGF-I to IGFBP-3 ratio and the change in HSDSCA, nor was there a significant differ ence betw een groups of the change in this ratio, although a trend was apparent after 30 months: the m ean change in IGF-I to IGFBP-3 ratio was 60, 82, and 81, for group A, B, and C. Also, neither IGF-I nor IGFBP-3 levels, nor their ratio were related to the pretreatm ent HV(sd score). Taken together, there is little evidence to support an explanation of the differences in grow th response betw een the groups by a change in the IGF-I to IGFBP-3 ratio. Nevertheless, a repeated measures model, w ith the dose-increment steps and duration of treatm ent as covariants, show ed that each change in HSDSCA correlated significantly with IGF-I plasm a levels. Thus, free IGF-I m ight still be a determining factor.
In contrast to an earlier study with an older group of girls with TS (32) , but in agreement with another report in TS (46) , the decrease in GHBP levels after 6 months treatment was not significant from baseline. This might be because of a large interindividual variation. At baseline there were no differ ences between groups. Most of the girls had GHBP levels within the normal age range, as shown previously (34) . At baseline a linear relationship between GHBP levels and age or stimulated GH levels at start of treatment in the present group of girls with TS was not observed, in contrast to earlier reports in normal children (34) . In agreement with the latter
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In conclusion, a stepwise GH-dosing approach reduced the waning effect of the growth response after 4 yr treatment without undue bone maturation. The increase in FH predic tion was not significantly different between treatment groups. Irrespective of the GH dose used, initiation of GH treatment at a younger age is beneficial in terms of cm gained either, at end of study or in terms of predicted FH, but not when expressed as the change in HSDSCA over the study period. The lower the baseline IGF-I and IGFBP-3 plasma levels as well as their ratio, and the higher the change in IGF-I and IGFBP-3 plasma levels, the greater is the change in HSDSca. The ultimate proof of the effect of the three GFI treatment regimens is FH. Therefore, the present treatment protocol will be extended until FH is reached.
